Functional Concept – Page 46

Eli Lilly and Insitro Collaborate on AI-Driven Therapies for Metabolic Diseases

9 months ago talkbio0Tagged Agreement, Antibody Therapy, Aortic Valve Insufficiency, Artificial Intelligence, Drug Development, Eli, Eli Lilly, Insitro, MASLD, Metabolic, Metabolic Diseases, RNA, Small Interfering, steatotic liver disease, strategic

Eli Lilly, Insitro, AI, Metabolic Diseases, Drug Development, Strategic Agreements, siRNA Therapies, Antibody Therapy, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

FDA Halts Kezar’s Lupus Nephritis Trial Due to Safety Concerns Following Four Patient Deaths

9 months ago talkbio0Tagged Cessation of life, concerns, Kezar Life Sciences, Lupus Nephritis, Safety, Study on Hold, United States Food and Drug Administration, Zetomipzomib

FDA, Kezar Life Sciences, lupus nephritis, zetomipzomib, clinical hold, patient deaths, safety concerns

AstraZeneca’s Airsupra Asthma Trial Halted Early Due to Overwhelming Efficacy, Paving Way for Regulatory Submission

9 months ago talkbio0Tagged Airsupra, Asthma, AstraZeneca, Clinical Trials, Effectiveness, overwhelming, regulatory

AstraZeneca, Airsupra, asthma treatment, clinical trial, overwhelming efficacy, regulatory submission

Scholar Rock Seeks $275M Funding Following Successful SMA Therapy Trial

9 months ago talkbio0Tagged Clinical Trials, pipeline, reshuffle, Scholar Rock, SMA, Spinal Muscular Atrophy, Vincerx

Scholar Rock, funding, SMA therapy, clinical trial, Vincerx, pipeline reshuffle

FDA Approves BMS’ Opdivo for Perioperative Treatment of Resectable Non-Small Cell Lung Cancer

10 months ago talkbio0Tagged Adjuvant Therapy, Approved, CheckMate-77 T trial, Neoadjuvant Therapy, nivolumab, Non-Small Cell Lung Carcinoma, Opdivo, perioperative, United States Food and Drug Administration

Opdivo (nivolumab), Perioperative treatment, Resectable non-small cell lung cancer (NSCLC), FDA approval, CheckMate-77T trial, Neoadjuvant and adjuvant therapy

BIOSECURE Act: Navigating Industry Implications and Future Directions

10 months ago talkbio0Tagged BIOSECURE, Biotechnology, capabilities, CDMOs, Chinese Language, Contract agreement, development aspects, Industry, Manufacture, manufacturing organizations, pharmaceutical imports, Pharmaceutical supply chain resilience, Supply chain disruptions, United States

BIOSECURE Act, Biotechnology industry, Supply chain disruptions, Chinese pharmaceutical imports, U.S. manufacturing capabilities, Contract development and manufacturing organizations (CDMOs), Pharmaceutical supply chain resilience

Gilead Expands HIV Drug Access, Yet Faces Criticism Over Exclusion of Middle-Income Countries

10 months ago talkbio0Tagged Exclusion Criteria, Generic licensing agreements, Gilead Sciences, HIV Drug Access, HIV prevention, Lenacapavir, middle-income countries, Pre-exposure, Pre-Exposure Prophylaxis

Gilead Sciences, HIV drug access, Lenacapavir, Generic licensing agreements, Middle-income countries exclusion, HIV prevention, Pre-exposure prophylaxis (PrEP)